{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:16:13Z","timestamp":1760170573111,"version":"3.40.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma and mantle cell lymphoma. We recently demonstrated that bortezomib eliminates autoreactive plasma cells in systemic lupus erythematosus mouse models, thereby representing a promising novel treatment for Ab-mediated diseases. In this study, we investigated the effects of bortezomib on the just developing and pre-existing T-dependent Ab response toward dinitrophenyl-keyhole limpet hemocyanin and the T-independent type 2 response toward (4-hydroxy-3-iodo-5-nitrophenyl)acetyl (NIP)-Ficoll in BALB\/c mice. Bortezomib treatment strongly reduced T-dependent Ab titers mainly due to depletion of plasma cells. In contrast, the early T-independent type 2 response against i.v. administered NIP-Ficoll, which is predominantly dependent on marginal zone (MZ) B cells, resisted bortezomib. Upon bortezomib treatment, immunoproteasome subunits and the antiapoptotic unfolded protein response including NF-\u03baB were induced in NIP-Ficoll\u2013stimulated MZ B cells, but not in plasma cells and follicular B cells. In summary, bortezomib treatment decreases Ab titers arising from T-dependent immune responses predominantly by eliminating plasma cells. In contrast, the early T-independent type 2 response protecting the organism against blood-borne pathogens remains largely intact due to a remarkable resistance of MZ B cells against proteasome inhibition.<\/jats:p>","DOI":"10.4049\/jimmunol.1001040","type":"journal-article","created":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T02:45:53Z","timestamp":1286246753000},"page":"5637-5647","source":"Crossref","is-referenced-by-count":14,"title":["The Early Marginal Zone B Cell-Initiated T-Independent Type 2 Response Resists the Proteasome Inhibitor Bortezomib"],"prefix":"10.1093","volume":"185","author":[{"given":"Veronika R","family":"Lang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Clinical Research Group, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Mielenz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Division of Molecular Immunology, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Neubert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Clinical Research Group, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Clinical Research Group, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Martin","family":"J\u00e4ck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Division of Molecular Immunology, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard E","family":"Voll","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Clinical Research Group, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Meister","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]},{"name":"Clinical Research Group, Institute of Clinical Immunology, Nikolaus-Fiebiger Center, University of Erlangen\u2013Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,11,1]]},"reference":[{"issue":"7","key":"2025032412054526300_r1","first-page":"12","article-title":"Current and emerging treatments for multiple myeloma","volume":"14","author":"Schwartz","year":"2008","journal-title":"J. Manag. Care Pharm."},{"key":"2025032412054526300_r2","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21414","article-title":"Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies","volume":"104","author":"Ludwig","year":"2005","journal-title":"Cancer"},{"key":"2025032412054526300_r3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2025032412054526300_r4","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-\u03baB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"2025032412054526300_r5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat. Med."},{"key":"2025032412054526300_r6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"2025032412054526300_r7","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"2025032412054526300_r8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4161\/cbt.5.7.2971","article-title":"Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress","volume":"5","author":"Fribley","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"2025032412054526300_r9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beha.2007.09.003","article-title":"Bortezomib in multiple myeloma","volume":"20","author":"Mateos","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"2025032412054526300_r10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev.immunol.23.021704.115728","article-title":"Marginal zone B cells","volume":"23","author":"Pillai","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"2025032412054526300_r11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1074-7613(01)00129-7","article-title":"Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens","volume":"14","author":"Martin","year":"2001","journal-title":"Immunity"},{"key":"2025032412054526300_r12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1365-2249.2002.01953.x","article-title":"The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens","volume":"130","author":"Zandvoort","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"2025032412054526300_r13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.cdd.4402297","article-title":"Proteasome inhibition drastically but reversibly impairs murine lymphocyte development","volume":"15","author":"Maseda","year":"2008","journal-title":"Cell Death Differ."},{"key":"2025032412054526300_r14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/eji.200737743","article-title":"Dampening Ab responses using proteasome inhibitors following in vivo B cell activation","volume":"38","author":"Cascio","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"2025032412054526300_r15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbamcr.2004.10.004","article-title":"The proteasome and MHC class I antigen processing","volume":"1695","author":"Kloetzel","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"2025032412054526300_r16","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells","volume":"65","author":"Altun","year":"2005","journal-title":"Cancer Res."},{"key":"2025032412054526300_r17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.23224","article-title":"Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits","volume":"112","author":"Busse","year":"2008","journal-title":"Cancer"},{"key":"2025032412054526300_r18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/scdb.1999.0318","article-title":"Role and regulation of the ER chaperone BiP","volume":"10","author":"Gething","year":"1999","journal-title":"Semin. Cell Dev. Biol."},{"key":"2025032412054526300_r19","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1101\/gad.12.7.982","article-title":"CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum","volume":"12","author":"Zinszner","year":"1998","journal-title":"Genes Dev."},{"key":"2025032412054526300_r20","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.molimm.2009.12.003","article-title":"CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells","volume":"47","author":"Masciarelli","year":"2010","journal-title":"Mol. Immunol."},{"key":"2025032412054526300_r21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"2025032412054526300_r22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J. Immunol."},{"key":"2025032412054526300_r23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.imbio.2009.06.018","article-title":"Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo","volume":"214","author":"Zinser","year":"2009","journal-title":"Immunobiology"},{"key":"2025032412054526300_r24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses essential immune functions of human CD4+ T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"key":"2025032412054526300_r25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.0105-2896.2004.0112.x","article-title":"Development and selection of marginal zone B cells","volume":"197","author":"Lopes-Carvalho","year":"2004","journal-title":"Immunol. Rev."},{"key":"2025032412054526300_r26","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1073\/pnas.0601502103","article-title":"B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses","volume":"103","author":"Hsu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032412054526300_r27","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"2025032412054526300_r28","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.4049\/jimmunol.177.6.3791","article-title":"Evidence that marginal zone B cells possess an enhanced secretory apparatus and exhibit superior secretory activity","volume":"177","author":"Gunn","year":"2006","journal-title":"J. Immunol."},{"key":"2025032412054526300_r29","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/leu.2009.8","article-title":"Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells","volume":"23","author":"Ruckrich","year":"2009","journal-title":"Leukemia"},{"key":"2025032412054526300_r30","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.4049\/jimmunol.167.4.1909","article-title":"Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines","volume":"167","author":"Weih","year":"2001","journal-title":"J. Immunol."},{"key":"2025032412054526300_r31","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-07-4470","article-title":"Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-\u03baB subunits in head and neck cancer","volume":"14","author":"Allen","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2025032412054526300_r32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00393-008-0427-x","article-title":"Depletion of plasma cells: a novel strategy in the therapy of systemic lupus erythematosus in mice and man","volume":"68","author":"Voll","year":"2009","journal-title":"Z. Rheumatol."},{"key":"2025032412054526300_r33","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2008-03-143461","article-title":"Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation","volume":"112","author":"Sun","year":"2008","journal-title":"Blood"},{"key":"2025032412054526300_r34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.transproceed.2008.10.073","article-title":"Proteasome inhibition reduces donor-specific antibody levels","volume":"41","author":"Everly","year":"2009","journal-title":"Transplant. Proc."},{"key":"2025032412054526300_r35","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"2025032412054526300_r36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2249.2001.01530.x","article-title":"Slow recovery of follicular B cells and marginal zone B cells after chemotherapy: implications for humoral immunity","volume":"124","author":"Zandvoort","year":"2001","journal-title":"Clin. Exp. Immunol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/185\/9\/5637\/61638649\/1001040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/185\/9\/5637\/61638649\/1001040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T02:11:37Z","timestamp":1743214297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/185\/9\/5637\/7981966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,1]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1001040","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"type":"print","value":"0022-1767"},{"type":"electronic","value":"1550-6606"}],"subject":[],"published-other":{"date-parts":[[2010,11]]},"published":{"date-parts":[[2010,11,1]]}}}